Full history for every metric is available with a Kvantra account
Intersect ENT, Inc. (XENT)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 79 | 96 | 108 | 109 | 81 | 107 | 104 |
| Operating profit | $m | -155 | -149 | |||||
| Net profit | $m | -25 | -16 | -23 | -43 | -72 | -160 | -170 |
| EPS reported | $ | -4.80 | -5.09 | |||||
| Operating cashflow per share | $ | -1.79 | -1.79 | |||||
| Capex per share | $ | 0.06 | 0.06 | |||||
| FCF per share | $ | -1.85 | -1.85 | |||||
| Free cash flow | $m | -61 | -71 | |||||
| Net debt | $m | 81 | 92 | |||||
| Book value equity | $m | -69 | -94 | |||||
| Book value per share | $ | -2.08 | -2.79 | |||||
| Number of shares | m | 33.27 | 33.74 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -13.16 | -10.13 | |||||
| P/S LTM | x | 8.51 | 9.16 | |||||
| P/FCF LTM | x | -14.78 | -13.37 | |||||
| EV/EBITDA LTM | x | -6.75 | -6.59 | |||||
| EV/Sales LTM | x | 9.48 | 10.05 | |||||
| Earnings Yield LTM | % | -17.57% | -16.99% | |||||
| FCF Yield | % | -6.77% | -7.48% | |||||
| Quality | ||||||||
| ROE | % | 231.12% | 15521.1% | |||||
| ROIC | % | -170.85% | -170.85% | |||||
| Operating margin | % | -145.10% | -145.10% | |||||
| Gross margin | % | 71.89% | 71.89% | |||||
| FCF/Sales | % | -57.60% | -57.60% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +32.52% | +22.27% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.43 | -0.45 | |||||
| Net Debt/EBITDA | x | -0.69 | -0.69 | |||||
| EBIT/Net interest | x | -24.06 | -24.06 | |||||
| Net debt/market cap | % | 8.92% | 9.65% | |||||
| Net debt/Equity | x | -1.17 | -0.98 | |||||
| Gross debt/equity | x | -2.06 | -1.68 | |||||
Company overview
Intersect ENT, Inc. is a medical technology firm focused on ear, nose, and throat (ENT) solutions, operating within the United States. Its product portfolio includes: PROPEL, PROPEL Mini, and PROPEL Contour: These are steroid-eluting implants. PROPEL is designed to maintain the patency of surgically enlarged sinuses, while PROPEL Mini targets patients undergoing frontal sinus procedures. PROPEL Contour specifically addresses the frontal and maxillary sinus ostia, or passages, within the dependent sinuses. SINUVA: Another steroid-releasing implant, intended for patient care in a clinical office environment. VENSURE Navigable and Stand-alone balloon: A sterile, single-use balloon device that facilitates access to and treatment of the frontal, sphenoid, and maxillary ostia in adult patients via a trans-nasal method. CUBE Navigation System: A digital guidance system offering high-accuracy navigation for ENT and associated skull-base surgical interventions. The company, originally established as Sinexus, Inc. in 2003, rebranded to Intersect ENT, Inc. in November 2009. Its corporate headquarters are located in Menlo Park, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Intersect ENT, Inc. (XENT)
Intersect ENT, Inc. is a medical technology firm focused on ear, nose, and throat (ENT) solutions, operating within the United States. Its product portfolio includes: PROPEL, PROPEL Mini, and PROPEL Contour: These are steroid-eluting implants. PROPEL is designed to maintain the patency of surgically enlarged sinuses, while PROPEL Mini targets patients undergoing frontal sinus procedures. PROPEL Contour specifically addresses the frontal and maxillary sinus ostia, or passages, within the dependent sinuses. SINUVA: Another steroid-releasing implant, intended for patient care in a clinical office environment. VENSURE Navigable and Stand-alone balloon: A sterile, single-use balloon device that facilitates access to and treatment of the frontal, sphenoid, and maxillary ostia in adult patients via a trans-nasal method. CUBE Navigation System: A digital guidance system offering high-accuracy navigation for ENT and associated skull-base surgical interventions. The company, originally established as Sinexus, Inc. in 2003, rebranded to Intersect ENT, Inc. in November 2009. Its corporate headquarters are located in Menlo Park, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free